# US 2024/0174724 A1 · Arenaviruses used in treatments of prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174724 A1
- Document ID: US20240174724A1
- Status: Published application
- Kind: A1
- Application number: 18/283,369
- Filed: 2022-03-22
- Published: 2024-05-30
- Earliest claimed: 2021-03-23
- Assignees: Hookipa Biotech GmbH
- Applicants: Hookipa Biotech GmbH
- Inventors: Igor Matushansky; Andy Hwang; Kianoosh Katchar; Henning Lauterbach; Klaus Orlinger; Sarah Schmidt; Felix Stemeseder
- Web page: https://patentgrep.com/patent/US20240174724A1

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 39/001193: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR}
- A61K 39/001194: {Prostate specific antigen [PSA]}
- A61K 39/001195: {Prostate specific membrane antigen [PSMA]}
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/16: acting on ester bonds (3.1)
- C12Y 301/03002: Acid phosphatase (3.1.3.2)
- C12Y 301/03005: 5'-Nucleotidase (3.1.3.5)
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/55511: {Organic adjuvants}
- C12N 2760/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/10043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present application relates to arenaviruses expressing prostate cancer-related antigens. In particular, described herein is a modified arenavirus particle which is engineered to carry a heterologous open reading frame (ORF) encoding a prostate cancer-related antigen or an antigenic fragment thereof, wherein the prostate cancer-related antigen is selected from the group consisting of: prostatic acid phosphatase (PAP), prostate specific antigen (PSA), and prostate-specific membrane antigen (PSMA). Also described herein are arenavius genome segments or S segments encoding the prostate cancer-related antigen or an antigenic fragment thereof, cDNA, DNA expression vector, a pharmaceutical composition comprising such an arenavirus particle, methods of generating such an arenavirus particle and treating prostate cancer using such an arenavirus particle, and a kit for such usage.

## Claims

### Claim 1

An arenavirus S segment, wherein the arenavirus S segment is engineered to carry an open reading frame (ORF) encoding a prostate cancer-related antigen or an antigenic fragment thereof, wherein the prostate cancer-related antigen is selected from the group consisting of: prostatic acid phosphatase (PAP), prostate specific antigen (PSA), and prostate-specific membrane antigen (PSMA).

### Claim 2 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding PAP or an antigenic fragment thereof in a position under control of an arenavirus 5′ UTR, and an ORF encoding arenaviral glycoprotein (GP) in a position under control of an arenavirus 3′ UTR.

### Claim 3 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding PAP or an antigenic fragment thereof in a position under control of an arenavirus 3′ UTR, and an ORF encoding GP in a position under control of an arenavirus 5′ UTR.

### Claim 4 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding PAP or an antigenic fragment thereof in a position under control of an arenavirus 5′ UTR, and an ORF encoding arenaviral nucleoprotein (NP) in a position under control of an arenavirus 3′ UTR.

### Claim 5 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding PAP or an antigenic fragment thereof in a position under control of an arenavirus 3′ UTR, and an ORF encoding NP in a position under control of an arenavirus 5′ UTR.

### Claim 6 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding PSA or an antigenic fragment thereof in a position under control of an arenavirus 5′ UTR, and an ORF encoding arenaviral glycoprotein (GP) in a position under control of an arenavirus 3′ UTR.

### Claim 7 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding PSA or an antigenic fragment thereof in a position under control of an arenavirus 3′ UTR, and an ORF encoding GP in a position under control of an arenavirus 5′ UTR.

### Claim 8 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding PSA or an antigenic fragment thereof in a position under control of an arenavirus 5′ UTR, and an ORF encoding arenaviral nucleoprotein (NP) in a position under control of an arenavirus 3′ UTR.

### Claim 9 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding PSA or an antigenic fragment thereof in a position under control of an arenavirus 3′ UTR, and an ORF encoding NP in a position under control of an arenavirus 5′ UTR.

### Claim 10 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding an antigenic fragment of PSMA in a position under control of an arenavirus 5′ UTR, and an ORF encoding arenaviral glycoprotein (GP) in a position under control of an arenavirus 3′ UTR.

### Claim 11 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding an antigenic fragment of PSMA in a position under control of an arenavirus 3′ UTR, and an ORF encoding GP in a position under control of an arenavirus 5′ UTR.

### Claim 12 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding an antigenic fragment of PSMA in a position under control of an arenavirus 5′ UTR, and an ORF encoding arenaviral nucleoprotein (NP) in a position under control of an arenavirus 3′ UTR.

### Claim 13 (depends on 1)

The arenavirus S segment of claim 1, wherein the arenavirus S segment is engineered to carry a heterologous ORF encoding an antigenic fragment of PSMA in a position under control of an arenavirus 3′ UTR, and an ORF encoding NP in a position under control of an arenavirus 5′ UTR.

### Claim 14 (depends on 2, 3, 4, 5)

The arenavirus S segment of any one of claims 2 to 5, wherein the amino acid sequence of the PAP or an antigenic fragment thereof comprises at least 80% or 90% identity to SEQ ID NO: 1.

### Claim 15 (depends on 6, 7, 8, 9)

The arenavirus S segment of any one of claims 6 to 9, wherein the amino acid sequence of the PSA or an antigenic fragment thereof comprises at least 80% or 90% identity to SEQ ID NO: 2.

### Claim 16 (depends on 10, 11, 12, 13)

The arenavirus S segment of any one of claims 10 to 13, wherein the amino acid sequence of the antigenic fragment of PSMA comprises at least 80% or 90% identity to SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 17 (depends on 2, 3, 4, 5)

The arenavirus S segment of any one of claims 2 to 5, wherein the amino acid sequence of the PAP or an antigenic fragment thereof comprises SEQ ID NO: 1.

### Claim 18 (depends on 2, 3, 4, 5)

The arenavirus S segment of any one of claims 2 to 5, wherein the amino acid sequence of the PAP or an antigenic fragment thereof comprises SEQ ID NO: 18.

### Claim 19 (depends on 6, 7, 8, 9)

The arenavirus S segment of any one of claims 6 to 9, wherein the amino acid sequence of the PSA or an antigenic fragment thereof comprises SEQ ID NO: 2.

### Claim 20 (depends on 10, 11, 12, 13)

The arenavirus S segment of any one of claims 10 to 13, wherein the amino acid sequence of the antigenic fragment of PSMA comprises SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 21 (depends on 2, 3, 4, 5)

The arenavirus S segment of any one of claims 2 to 5, wherein the amino acid sequence of the PAP or an antigenic fragment thereof consists of SEQ ID NO: 1.

### Claim 22 (depends on 2, 3, 4, 5)

The arenavirus S segment of any one of claims 2 to 5, wherein the amino acid sequence of the PAP or an antigenic fragment thereof consists of SEQ ID NO: 18.

### Claim 23 (depends on 6, 7, 8, 9)

The arenavirus S segment of any one of claims 6 to 9, wherein the amino acid sequence of the PSA or an antigenic fragment thereof consists of SEQ ID NO: 2.

### Claim 24 (depends on 10, 11, 12, 13)

The arenavirus S segment of any one of claims 10 to 13, wherein the amino acid sequence of the antigenic fragment of PSMA consists of SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 25 (depends on 2, 3, 4, 5)

The arenavirus S segment of any one of claims 2 to 5, wherein the nucleotide sequence of the ORF encoding the PAP or an antigenic fragment thereof comprises at least 50%, 60%, 70%, 80%, or 90% identity to SEQ ID NO: 5.

### Claim 26 (depends on 6, 7, 8, 9)

The arenavirus S segment of any one of claims 6 to 9, wherein the nucleotide sequence of the ORF encoding the PSA or an antigenic fragment thereof comprises at least 50%, 60%, 70%, 80%, or 90% identity to SEQ ID NO: 6.

### Claim 27 (depends on 10, 11, 12, 13)

The arenavirus S segment of any one of claims 10 to 13, wherein the nucleotide sequence of the ORF encoding the antigenic fragment of PSMA comprises at least 50%, 60%, 70%, 80%, or 90% identity to SEQ ID NO: 7 or SEQ ID NO: 8.

### Claim 28 (depends on 2, 3, 4, 5)

The arenavirus S segment of any one of claims 2 to 5, wherein the nucleotide sequence of the ORF encoding the PAP or an antigenic fragment thereof comprises SEQ ID NO: 5.

### Claim 29 (depends on 6, 7, 8, 9)

The arenavirus S segment of any one of claims 6 to 9, wherein the nucleotide sequence of the ORF encoding the PSA or an antigenic fragment thereof comprises SEQ ID NO: 6.

### Claim 30 (depends on 10, 11, 12, 13)

The arenavirus S segment of any one of claims 10 to 13, wherein the nucleotide sequence of the ORF encoding the antigenic fragment of PSMA comprises SEQ ID NO: 7 or SEQ ID NO: 8.

### Claim 31 (depends on 2, 3, 4, 5)

The arenavirus S segment of any one of claims 2 to 5, wherein the nucleotide sequence of the ORF encoding the PAP or an antigenic fragment thereof consists of SEQ ID NO: 5.

### Claim 32 (depends on 6, 7, 8, 9)

The arenavirus S segment of any one of claims 6 to 9, wherein the nucleotide sequence of the ORF encoding the PSA or an antigenic fragment thereof consists of SEQ ID NO: 6.

### Claim 33 (depends on 10, 11, 12, 13)

The arenavirus S segment of any one of claims 10 to 13, wherein the nucleotide sequence of the ORF encoding the antigenic fragment of PSMA consists of SEQ ID NO: 7 or SEQ ID NO: 8.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A cDNA of the arenavirus S segment of any one of claims 1 to 33.

### Claim 35 (depends on 34)

A DNA expression vector comprising the cDNA of claim 34.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A host cell comprising the arenavirus S segment of any one of claims 1 to 33, the cDNA of claim 34, or the vector of claim 35.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A tri-segmented arenavirus particle comprising one arenavirus L segment and two arenavirus S segments, wherein the two arenavirus S segments are any one of claims 1 to 33, and wherein one of the two arenavirus S segments comprises GP and the other comprises NP.

### Claim 38 (depends on 37)

The tri-segmented arenavirus particle of claim 37, wherein the tri-segmented arenavirus particle has stable expression of the prostate cancer-related antigen or an antigenic fragment thereof after being passaged at least 4, 5, 6, 7, 8, 9, or 10 generations.

### Claim 39

A tri-segmented arenavirus particle comprising one arenavirus L segment and two arenavirus S segments, wherein a first arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO: 5 in a position under control of an arenavirus 5′ UTR and an ORF encoding arenaviral nucleoprotein (NP) in a position under control of an arenavirus 3′ UTR, and a second arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO: 6 in a position under control of an arenavirus 5′ UTR and an ORF encoding arenaviral glycoprotein (GP) in a position under control of an arenavirus 3′ UTR.

### Claim 40

A tri-segmented arenavirus particle comprising one arenavirus L segment and two arenavirus S segments, wherein a first arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO: 8 in a position under control of an arenavirus 5′ UTR and an ORF encoding arenaviral nucleoprotein (NP) in a position under control of an arenavirus 3′ UTR, and a second arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO: 7 in a position under control of an arenavirus 5′ UTR and an ORF encoding arenaviral glycoprotein (GP) in a position under control of an arenavirus 3′ UTR.

### Claim 41

A tri-segmented arenavirus particle comprising one arenavirus L segment and two arenavirus S segments, wherein a first arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO: 7 in a position under control of an arenavirus 5′ UTR and an ORF encoding arenaviral nucleoprotein (NP) in a position under control of an arenavirus 3′ UTR, and a second arenavirus S segment is engineered to carry a heterologous ORF consisting of SEQ ID NO: 8 in a position under control of an arenavirus 5′ UTR and an ORF encoding arenaviral glycoprotein (GP) in a position under control of an arenavirus 3′ UTR.

### Claim 42 (depends on 37, 38, 39, 40, 41)

The tri-segmented arenavirus particle of any one of claims 37 to 41, wherein the tri-segmented arenavirus particle is derived from lymphocytic choriomeningitis virus (LCMV) or Pichinde virus (PICV).

### Claim 43 (depends on 42)

The tri-segmented arenavirus particle of claim 42, wherein the tri-segmented arenavirus particle is derived from LCMV.

### Claim 44 (depends on 43)

The tri-segmented arenavirus particle of claim 43, wherein said LCMV is MP strain, WE strain, an LCMV clone 13 expressing the glycoprotein of LCMV strain WE instead of the endogenous LCMV clone 13 glycoprotein, Armstrong strain, or Armstrong Clone 13 strain.

### Claim 45 (depends on 42)

The tri-segmented arenavirus particle claim 42, wherein the tri-segmented arenavirus particle is derived from PICV.

### Claim 46 (depends on 45)

The tri-segmented arenavirus particle claim 45, wherein said PICV is strain Munchique CoAn4763 isolate P18, or P2 strain.

### Claim 47

A tri-segmented arenavirus particle comprising two S segments, wherein one of the two S segments comprises SEQ ID NO. 10, and the other one of the two S segments comprises SEQ ID NO. 11.

### Claim 48

A tri-segmented arenavirus particle comprising two S segments, wherein one of the two S segments comprises SEQ ID NO. 12, and the other one of the two S segments comprises SEQ ID NO. 13.

### Claim 49

A tri-segmented arenavirus particle comprising two S segments, wherein one of the two S segments comprises SEQ ID NO. 14, and the other one of the two S segments comprises SEQ ID NO. 15.

### Claim 50

A tri-segmented arenavirus particle comprising two S segments, wherein one of the two S segments comprises SEQ ID NO. 16, and the other one of the two S segments comprises SEQ ID NO. 17.

### Claim 51 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The tri-segmented arenavirus particle of any one of claims 37 to 50, wherein the tri-segmented arenavirus particle is infectious and replication competent.

### Claim 52 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The tri-segmented arenavirus particle of any one of claims 37 to 50, wherein the tri-segmented arenavirus particle is attenuated.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method of generating a tri-segmented arenavirus particle, wherein the method comprises:
(i) transfecting into a host cell the nucleic acids of two arenavirus S segments and one arenavirus L segment, wherein the two arenavirus S segments are any one of claims 1 to 33;
(ii) maintaining the host cell under conditions suitable for virus formation; and
(iii) harvesting the cell culture supernatant containing the arenavirus particle.

### Claim 54 (depends on 53)

The method of claim 53, wherein the transcription of the arenavirus L segment and the two arenavirus S segments is performed using a bidirectional expression cassette.

### Claim 55 (depends on 53, 54)

The method of claim 53 or 54, wherein the method further comprises transfecting one or more nucleic acids encoding an arenavirus polymerase into the host cell.

### Claim 56 (depends on 55)

The method of claim 55, wherein the arenavirus polymerase is the arenavirus L protein.

### Claim 57 (depends on 53, 54, 55, 56)

The method of any one of claims 53 to 56, wherein the method further comprises transfecting one or more nucleic acids encoding the arenavirus NP protein into the host cell.

### Claim 58 (depends on 53, 54, 55, 56, 57)

The method of any one of claims 53 to 57, wherein the nucleic acids are encoded in cDNA.

### Claim 59 (depends on 53, 54, 55, 56, 57)

The method of any one of claims 53 to 57, wherein the nucleic acids are encoded in RNA.

### Claim 60 (depends on 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 53 to 59, wherein transcription of the arenavirus L segment and the two arenavirus S segments are each under the control of a promoter.

### Claim 61 (depends on 58)

The method of claim 58, wherein the promoter is selected from the group consisting of:
(i) a RNA polymerase I promoter;
(ii) a RNA polymerase II promoter; and
(iii) a T7 promoter.

### Claim 62 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A pharmaceutical composition comprising an arenavirus particle of any one of claims 37 to 52, and a pharmaceutically acceptable carrier.

### Claim 63 (depends on 62)

A method for treating prostate cancer comprising administering to a subject in need thereof the pharmaceutical composition of claim 62 in a therapeutically effective amount.

### Claim 64 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A method for treating prostate cancer in a subject in need thereof, wherein the method comprises:
(i) administering to the subject a first pharmaceutical composition, wherein the first pharmaceutical composition comprises one or more arenavirus particles of any one of claims 37 to 52; and
(ii) administering to the subject, after a period of time, a second pharmaceutical composition, wherein the second pharmaceutical composition comprises one or more arenavirus particles of any one of claims 37 to 52.

### Claim 65 (depends on 64)

The method of claim 64, wherein the method further comprises repeating (i) and (ii).

### Claim 66 (depends on 64, 65)

The method of claim 64 or 65, wherein the first and the second pharmaceutical compositions are administered intravenously or intratumorally.

### Claim 67 (depends on 64, 65, 66)

The method of any one of claims 64 to 66, wherein the one or more arenavirus particles from the first pharmaceutical composition are derived from a different arenavirus species but carry ORF(s) encoding the same prostate cancer-related antigens or antigenic fragments thereof, when compared to the one or more arenavirus particles from the second pharmaceutical composition.

### Claim 68 (depends on 67)

The method of claim 67, wherein the one or more arenavirus particles from the first pharmaceutical composition are derived from PICV, and the one or more arenavirus particles from the second pharmaceutical composition are derived from LCMV.

### Claim 69 (depends on 47, 48, 64, 65, 66, 67, 68)

The method of any one of claims 64 to 68, wherein the one or more arenavirus particles from the first pharmaceutical composition is the tri-segmented arenavirus particle of claim 48, and the one or more arenavirus particles from the second pharmaceutical composition is the tri-segmented arenavirus particle of claim 47,

### Claim 70 (depends on 47, 48, 49, 50, 64, 65, 66, 67, 68)

The method of any one of claims 64 to 68, wherein the one or more arenavirus particles from the first pharmaceutical composition are the tri-segmented arenavirus particles of claim 48 and claim 50, and the one or more arenavirus particles from the second pharmaceutical composition are the tri-segmented arenavirus particles of claim 47 and claim 49.

### Claim 71 (depends on 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 64 to 70, wherein a second agent is administered in combination with the first and/or the second pharmaceutical composition.

### Claim 72 (depends on 71)

The method of claim 71, wherein the second agent is an agent to treat prostate cancer.

### Claim 73 (depends on 72)

The method of claim 72, wherein the second agent is selected from the group consisting of docetaxel, mitoxantrone, cabazitaxel, and pembrolizumab.

### Claim 74 (depends on 72)

The method of claim 72, wherein the second agent is selected from the group consisting of enzalutamide and abiraterone.

### Claim 75 (depends on 72, 73, 74)

The method of any one of claims 72 to 74, wherein the second agent is administered with a steroid.

### Claim 76 (depends on 75)

The method of claim 75, wherein the steroid comprises prednisone or methylprednisolone.

### Claim 77 (depends on 71, 72, 73, 74, 75, 76)

The method of any one of claims 71 to 76, wherein the first and/or the second pharmaceutical composition and the second agent are co-administered simultaneously.

### Claim 78 (depends on 71, 72, 73, 74, 75, 76)

The method of any one of claims 71 to 76, wherein the first and/or the second pharmaceutical composition is administered prior to administration of the second agent.

### Claim 79 (depends on 71, 72, 73, 74, 75, 76)

The method of any one of claims 71 to 76, wherein the first and/or the second pharmaceutical composition is administered after administration of the second agent.

### Claim 80 (depends on 78, 79)

The method of any one of claims 78 to 79, wherein the interval between administration of the pharmaceutical composition(s) and the second agent is about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.

### Claim 81 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 63 to 80, wherein the subject is suffering from, is susceptible to, or is at risk for prostate cancer.

### Claim 82 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A kit comprising a container and an instruction for use, wherein the container comprises an arenavirus particle of any one of claims 37 to 52, and optionally wherein the arenavirus particle is in a pharmaceutical composition suitable for intravenous administration.

### Claim 83 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A kit comprising two or more containers and an instruction for use, wherein one of the containers comprises an arenavirus particle of any one of claims 37 to 52, and another of the containers comprises a second agent, and optionally wherein the arenavirus particle is in a pharmaceutical composition suitable for intravenous administration.

### Claim 84 (depends on 82, 83)

The kit of any one of claims 82 to 83, wherein the kit further comprises an apparatus suitable for performing intravenous administration.
